These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12379357)

  • 1. Detection strategies for catalytic antibodies.
    Reymond JL
    J Immunol Methods; 2002 Nov; 269(1-2):125-31. PubMed ID: 12379357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A catalytic antibody against a tocopherol cyclase inhibitor.
    Manetsch R; Zheng L; Reymond MT; Woggon WD; Reymond JL
    Chemistry; 2004 May; 10(10):2487-506. PubMed ID: 15146522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient and selective p-nitrophenyl-ester-hydrolyzing antibodies elicited by a p-nitrobenzyl phosphonate hapten.
    Tawfik DS; Lindner AB; Chap R; Eshhar Z; Green BS
    Eur J Biochem; 1997 Mar; 244(2):619-26. PubMed ID: 9119032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Directed evolution governed by controlling the molecular recognition between an abzyme and its haptenic transition-state analog.
    Takahashi-Ando N; Kakinuma H; Fujii I; Nishi Y
    J Immunol Methods; 2004 Nov; 294(1-2):1-14. PubMed ID: 15604011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catalytic antibodies: hapten design strategies and screening methods.
    Xu Y; Yamamoto N; Janda KD
    Bioorg Med Chem; 2004 Oct; 12(20):5247-68. PubMed ID: 15388154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catalytic antibodies for complex reactions: hapten design and the importance of screening for catalysis in the generation of catalytic antibodies for the NDA/CN reaction.
    DeSilva BS; Orosz G; Egodage KL; Carlson RG; Schowen RL; Wilson GS
    Appl Biochem Biotechnol; 2000; 83(1-3):195-206; discussion 206-8, 297-313. PubMed ID: 10826960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catalytic antibodies that hydrolyze (-)-cocaine obtained by a high-throughput procedure.
    Cashman JR; Berkman CE; Underiner GE
    J Pharmacol Exp Ther; 2000 Jun; 293(3):952-61. PubMed ID: 10869397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.
    Wenthur CJ; Cai X; Ellis BA; Janda KD
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3666-3668. PubMed ID: 28709828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An improved rapid method for selecting monoclonal antibodies with high catalytic activities.
    Yuan YR; Yang BH; Ji YY
    J Protein Chem; 1997 Nov; 16(8):733-8. PubMed ID: 9365921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyridoxal-5'-phosphate-dependent catalytic antibodies.
    Gramatikova S; Mouratou B; Stetefeld J; Mehta PK; Christen P
    J Immunol Methods; 2002 Nov; 269(1-2):99-110. PubMed ID: 12379355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pivalase catalytic antibodies: towards abzymatic activation of prodrugs.
    Bensel N; Reymond MT; Reymond JL
    Chemistry; 2001 Nov; 7(21):4604-12. PubMed ID: 11757652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of flexible and constrained haptens in eliciting antibody catalysts for paraoxon hydrolysis.
    Spivak DA; Hoffman TZ; Moore AH; Taylor MJ; Janda KD
    Bioorg Med Chem; 1999 Jun; 7(6):1145-50. PubMed ID: 10428386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunological evolution of catalysis.
    Patten PA; Gray NS; Yang PL; Marks CB; Wedemayer GJ; Boniface JJ; Stevens RC; Schultz PG
    Science; 1996 Feb; 271(5252):1086-91. PubMed ID: 8599084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A common ancestry for multiple catalytic antibodies generated against a single transition-state analog.
    Miyashita H; Hara T; Tanimura R; Tanaka F; Kikuchi M; Fujii I
    Proc Natl Acad Sci U S A; 1994 Jun; 91(13):6045-9. PubMed ID: 8016113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new visual screening assay for catalytic antibodies with retro-aldol retro-Michael activity.
    Shamis M; Barbas CF; Shabat D
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1172-5. PubMed ID: 17234408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Origins and predictions of stereoselective antibody catalysis: theoretical analysis of Diels-Alder catalysis by 39A11 and its germ-line antibody.
    Zhang X; Deng Q; Yoo SH; Houk KN
    J Org Chem; 2002 Dec; 67(25):9043-53. PubMed ID: 12467427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
    Ulrich HD; Schultz PG
    J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. catELISA: a facile general route to catalytic antibodies.
    Tawfik DS; Green BS; Chap R; Sela M; Eshhar Z
    Proc Natl Acad Sci U S A; 1993 Jan; 90(2):373-7. PubMed ID: 7678455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing ligand recognition in the decarboxylase antibody 21D8: implications for the catalytic mechanism.
    Hotta K; Wilson IA; Hilvert D
    Biochemistry; 2002 Jan; 41(3):772-9. PubMed ID: 11790098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune recognition, antigen design, and catalytic antibody production.
    Tramontano A
    Appl Biochem Biotechnol; 1994; 47(2-3):257-73; discussion 273-5. PubMed ID: 7944342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.